Back

Adrenaline enhances nociceptive and motor blockades by intrathecal carteolol and oxprenolol in rats.

  • Published In: Fundamental & Clinical Pharmacology, 2025, v. 39, n. 2. P. 1 1 of 3

  • Database: Academic Search Ultimate 2 of 3

  • Authored By: Chiu, Chong‐Chi; Liu, Kuo‐Sheng; Liu, Chieh‐Yu; Hung, Ching‐Hsia; Chen, Yu‐Wen; Wang, Jhi‐Joung 3 of 3

Abstract

Background: This study examined the effects of beta‐blockers and the combination of carteolol/oxprenolol with epinephrine on spinal nociceptive and motor blockades and compared them with propranolol. Methods: Nociceptive and motor blockades were assessed in rats after intrathecal injection of carteolol, oxprenolol, metoprolol, acebutolol, and sotalol. Carteolol and oxprenolol were used in combination with epinephrine for spinal nociceptive and motor blockades. Propranolol was used as a control. Results: At the same dose of 0.6 μmol, carteolol and oxprenolol are more potent than propranolol, and the duration of action of carteolol and oxprenolol is longer than or the same as that of propranolol. At ED50 (50% effective dose), the potency rankings of drugs are carteolol > oxprenolol > propranolol (P > 0.01). At ED25, ED50, and ED75, the time to full recovery induced by carteolol was longer than that induced by oxprenolol or propranolol. When 1:40,000 epinephrine was added to beta‐blocker (carteolol, oxprenolol, and propranolol) at ED50, spinal blockades and duration of action were increased compared to beta‐blockers alone (P > 0.05). Conclusion: Carteolol and oxprenolol are more effective than propranolol on spinal blockades, while other beta‐blockers are relatively ineffective. Compared to propranolol, the duration of action of carteolol and oxprenolol is longer or the same. Epinephrine enhances spinal blockades of carteolol, oxprenolol, and propranolol, suggesting that alpha‐adrenergic receptors may play an important role in enhancing the anti‐nociceptive effects of beta‐blockers. [ABSTRACT FROM AUTHOR]

Additional Information

  • Source:Fundamental & Clinical Pharmacology. 2025/03, Vol. 39, Issue 2, p1
  • Document Type:Article
  • Subject Area:Consumer Health
  • Publication Date:2025
  • ISSN:0767-3981
  • DOI:10.1111/fcp.70003
  • Accession Number:184019429
  • Copyright Statement:Copyright of Fundamental & Clinical Pharmacology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Looking to go deeper into this topic? Look for more articles on EBSCOhost.